KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601.

Gopa Iyer, Woonyoung Choi, Bin Luo, Filipe Carvalho, Timothy Hanlon, Henning Reis, Brendan J Guercio, Megan Fong, Jack Mountain, Mingxiao Feng, Ashley M Regazzi, Linda McCart, Yujia Wen, Hikmat Al-Ahmadie, Kent W Mouw, Eliezer M Van Allen, Joaquim Bellmunt, Robert Dreicer, Thomas W Flaig, Susan Halabi, David J McConkey, Jonathan E Rosenberg

JCO Precis Oncol 9 e2400938

PMID40591902
PMCIDPMC12713149
DOI10.1200/PO-24-00938
发表日期2025-07-01
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:森林图/亚组分析图;Figure 3.:非 KM 图;Figure 4.:森林图/亚组分析图;Figure 5.:非 KM 图。
摘要

摘要

PURPOSE: In urothelial carcinoma, prior studies have indicated that the basal/squamous molecular subtype and the presence of select DNA damage response (DDR) gene alterations are associated with improved benefit from cisplatin-based chemotherapy. We sought to evaluate these biomarkers in specimens from the phase III Cancer and Leukemia Group B (CALGB) 90601 trial. METHODS: We performed whole-transcriptome sequencing (n = 188) and exon capture DNA sequencing (n = 208) on pretreatment tumors from the CALGB 90601 randomized trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with treatment-naïve metastatic bladder cancer. Whole-exome sequencing (WES) was performed on tumors from 22 patients who exhibited rapid progression or durable response. Tumors were assigned to molecular subtypes using three different classifiers. Proportional hazards model was used to correlate molecular subtype with overall survival (OS) and progression-free survival (PFS), adjusting for stratification factors and treatment arm (for PFS). RESULTS: Patients with basal tumors had the shortest PFS and OS in the entire cohort. PFS was numerically longer in patients with basal tumors receiving bevacizumab. DDR gene alterations were not associated with improved outcomes. FRY, a candidate predictive biomarker of chemosensitivity identified by WES, did not confer sensitivity to cisplatin or gemcitabine in functional studies. CONCLUSION: Molecular subtype and DDR alterations did not correlate with improved outcomes in CALGB 90601. Possible explanations for these results include the small cohort size, lack of strong therapeutic effects of the treatments, genomic heterogeneity between profiled specimens and the metastatic lesions under treatment pressure, and differences in biology associated with different disease states (muscle-invasive v metastatic disease).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Disposition of Specimens. Breakdown of analyzed specimens. *Specimens for 170 patients were not available either due to lack of tissue submission by participating site or inadequate tissue for further correlative analysis JHU, Johns Hopkins University
非 KM Figure
Figure 2.Association of deleterious DDR gene alterations and ERCC2 with survival outcomes. Association of deleterious DDR gene alterations as defined in trial A031701 with A) progression-free survival (PFS) and B) overall survival (OS). The presence of the deleterious DDR mutations was not associated with progression-free survival or overall survival in CALGB 90601 (PFS HR 0.74, 95% CI 0.48–1.12, p=0.15; OS HR 0.77, 95% CI 0.50 – 1.18, p=0.22). Associations of ERCC2 alterations with C) PFS and D) OS. ERCC2 mutations did not significantly impact PFS or OS in patients treated on CALGB 90601 (PFS HR 0.64, 95% CI 0.33–1.25, p=0.19; OS: HR 0.65, 95% CI 0.32–1.32, p=0.23). Figure insets denote median survival with 95% confidence intervals. CI, confidence interval; DDR, DNA damage response; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; NE, not estimable; WT, wild-type
非 KM Figure
Figure 3.Correlation of molecular subtypes with expression of signature genes. Tumors were assigned to the MD Anderson (MDA), BASE47, and Consensus subtypes as described in the Methods and were organized according to the MD Anderson subtype calls. Canonical subtype-associated gene expression signatures were evaluated to confirm the robustness of the subtype assignments. The FGFR3, early cell cycle (ECC), and late cell cycle (LCC) signatures were derived from Sjodahl et al (PMID: 22553347). Ba/Sq, basal/squamous; ECC, early cell cycle; LCC, late cell cycle; LumP, luminal papillary; LumU, luminal unstable; MDA, MD Anderson; NE-like, neuroendocrine-like
非 KM Figure
Figure 4.Survival outcomes stratified by molecular subtype membership (MDA). Figure insets denote either median survival with 95% confidence intervals or hazard ratios with 95% confidence intervals. HR, hazard ratio
非 KM Figure
Figure 5.Association of molecular subtype and gene expression signatures with hypoxia, angiogenesis, or tumor-associated stromal cells. (A) Gene set variation analyses (GSVA) were carried out using 5 different public gene expression signatures associated with hypoxia, angiogenesis, or stromal cells. The strength of each association is depicted by the color intensity in the heat map (red = positively associated, green = negatively associated). (B) Graphical depiction of the GSVA results obtained with the public hypoxia signatures and expression of the IPA HIF signature displayed according to the MDA molecular subtypes. Levels of statistical significance for each comparison are shown. Ba/Sq, basal/squamous; HIF, hypoxia-inducible factor; IPA, Ingenuity Pathway Analysis; LumNS, luminal non-specified; LumP, luminal papillary; LumU, luminal unstable; MDA, MD Anderson; NE-like, neuroendocrine-like; Ns, not significant *p<0.05; **p< 0.01; ***p<0.001; ****p<0.0001.
非 KM Figure